Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
15 avr. 2021 07h00 HE
|
Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
30 mars 2021 07h57 HE
|
Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
Arch Biopartners Closes Non-Brokered Private Placement
29 déc. 2020 08h33 HE
|
Arch Biopartners
TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Empowering Faith Communities to Champion Black Health Equity Amid A Pandemic
28 oct. 2020 17h41 HE
|
The Balm In Gilead Inc.
RICHMOND, Va., Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Balm In Gilead Inc. is a leader in bringing public health and faith communities together to strategically address health disparities in the...
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
09 janv. 2020 07h30 HE
|
Scholar Rock
Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...